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ABSTRACT
Background. Neoadjuvant chemoradiotherapy (CRT) is now
considered the standardof carebymanycenters in the treatment
of both squamous cell carcinoma (SCC) and adenocarcinoma
of the esophagus. This study evaluates the effectiveness of a
neoadjuvant CRT protocol, as regards pathological complete
response (pCR) rate and long-term survival.
Methods. From 2003 to 2011, at Upper G.I. Surgery Divi-
sion of Verona University, 155 consecutive patients with
locally advanced esophageal cancers (90 SCC, 65 adeno-
carcinoma) were treated with a single protocol of
neoadjuvant CRT (docetaxel, cisplatin, and 5-fluorouracil
with 50.4 Gy of concurrent radiotherapy). Response to CRT
was evaluated through percentage of pathological complete
response (pCR or ypT0N0), overall (OS) and disease-related
survival (DRS), and pattern of relapse.
Results. One hundred thirty-one patients (84.5 %) under-
went surgery. Radical resection (R0) was achieved in 123
patients (79.3 %), and pCR in 65 (41.9 %). Postoperative
mortality was 0.7 % (one case). Five-year OS and DRS
were respectively 43 and 49 % in the entire cohort, 52 and
59 % in R0 cases, and 72 and 81 % in pCR cases. Survival
did not significantly differ between SCC and adenocarci-
noma, except for pCR cases. Forty-nine patients suffered
from relapse, which was mainly systemic in adenocarci-
noma. Only three out of 26 pCR patients with previous
adenocarcinoma developed relapse, always systemic.
Conclusions. This study suggests that patients treated with
the present protocol achieve good survival and high pCR
rate. Further research is necessary to evaluate whether
surgery on demand is feasible in selected patients, such as
pCR patients with adenocarcinoma.
Despite remarkable improvements in surgical technique,
survival with surgery alone in locally advanced esophageal
cancer remains poor, with median 5-year overall survival
not exceeding 20 %.1,2
This prompted the introduction of multimodal approa-
ches: neoadjuvant chemoradiotherapy (CRT) increases
local control and improves survival according to recent
meta-analyses of randomized trial and the recently pub-
lished randomized CROSS trial.3–7
Responders to treatment have better prognosis than
nonresponders.8 Patients are defined as pathological com-
plete responders (pCR) when residual tumor is detected
neither at primary site nor in lymph nodes, representing the
best possible response to induction treatment.8 In an effort
to implement a tailored treatment strategy, pCR patients
could be considered a group that is probably overtreated, as
they might not need surgery. However, surgery is still
mandatory even in patients with the best prognosis, as
rigorous assessment of clinical response is still lacking.
The present study aims to evaluate the effect of a pro-
tocol of concurrent neoadjuvant CRT on overall survival
(OS) and disease-related survival (DRS), and on radical
resection (R0) and pCR rate. Recurrence rate and pattern of
recurrence were also evaluated.
PATIENTS AND METHODS
From 2003 to 2011, at Upper G.I. Surgery Division of Ve-
rona University, 155 consecutive patients with locally
advanced esophageal cancers (90 SCC, 65 adenocarcinoma
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Siewert type I and II) were treated with a single protocol of
neoadjuvant concurrent CRT. All patients gave informed
consent and met the following inclusion criteria: locally
advanced carcinoma [cT2–4 Nx M0, according to the clinical
tumor–node–metastasis (cTNM) classification, reclassified
according to the seventh edition], no other cancers or che-
motherapy/radiotherapy in the previous 5 years, age 75 years
or less, and good Eastern Cooperative Oncology Group per-
formance status (ECOG grade 0–2). Clinical stage was
evaluated by computed tomography (CT), endoscopy, and
endosonography. Positron emission tomography (PET)/CT
scans were routinely available since 2008.
The protocol adopted has been fully described previ-
ously.9 Briefly it consisted of 5-fluorouracil (5-FU),
cisplatin, and docetaxel (Taxotere; Sanofi-Aventis, Paris,
France) along with 50.4 Gy of concurrent radiotherapy.
The schedule was: 5-FU 150 mg/m2 per day on day 1 and
21 by continuous infusion; cisplatin 20 mg/m2 on day 1, 8,
15, 28, 35, and 42; docetaxel 20 mg/m2 on day 1, 8, 15, 28,
35, and 42. Radiotherapy started on day 28 along with the
second chemotherapy cycle. Patients were treated for
5 days a week with a 1.8 Gy/day dosage for a total radia-
tion dose of 50.4 Gy. Surgery was performed 6–8 weeks
after completion of the treatment.
The standard surgical procedure was a modified Ivor–
Lewis, consisting of proximal gastrectomy and subtotal
esophagectomy with D1? abdominal and standard medias-
tinal (two-field) lymphadenectomy. The continuity of the
digestive tract was achieved with a right intrathoracic supra-
azygotic esophagogastric end-to-end anastomosis with a
narrow gastric tube (3 cmwide). Patientswith upper thoracic
SCC were instead treated with a McKeown procedure with
cervical esophagogastric or pharyngogastric anastomosis.
All resected specimens were histopathologically exam-
ined. The visible tumor or suspected tumor areas were
measured and completely included, and serial 4–5-lm
sections were stained with hematoxylin and eosin. Treat-
ment-induced response at the primary tumor site was
evaluated according to the size of residual cancer according
to Size-based Pathological Response (SPR) classification,
which groups tumor regression into four classes: (1)
pathological complete response (pCR) (ypT0 N0), (2)
minimal residual disease (MRD) (residual foci B1 cm,
ypN0), (3) nonresponse (NR) (foci[1 cm, ypN0), and (4)
node-positive cases (ypN?).8
Response to CRT was evaluated through percentage of
pCR and R0, and overall (OS) and disease-related survival
(DRS). R status was defined as absence or presence of
infiltrated margins. The circumferential resection margin
was considered positive if the gap between the tumor and
the margin was\1 mm.
Rate and pattern of relapse were also evaluated. For this
purpose, patients were regularly followed up every
6 months. When symptoms were reported, they were
immediately investigated. Recurrence was detected by
computed tomography, endoscopy, and PET/CT scans.
Locoregional recurrences were defined as recurrences in
the surgical bed, at anastomotic level, or more frequently,
in locoregional nodes. Systemic recurrence comprised both
hematological and distant nodal relapses. When recurrence
was simultaneously detected at both systemic and locore-
gional level, it was classified as mixed.
Statistical Analysis
Significance of differences between SCC and adeno-
carcinoma groups was computed by Fisher’s exact test for
qualitative variables and Wilcoxon–Mann–Whitney rank-
sum test for quantitative variables.
The life status of individual patients was ascertained on
31 December 2011, no patient being lost to follow-up.
Median follow-up in surviving patients was 46 months
(range 6–107 months). Overall and disease-related survival
were computed; the latter was calculated considering as
terminal events both postoperative deaths, defined as
deaths occurring within the first 30 days after surgery or in
hospital, and deaths from recurrence, while patients dying
from other causes were considered as censored observa-
tions at the time of death.
Survival curves were estimated by the Kaplan–Meier
method and compared by the log-rank test for trend.10
RESULTS
Surgery
The demographic and clinical characteristics of the
present series are displayed in Table 1. Nearly all patients
with adenocarcinoma were male, while females represented
about 25 % of patients with SCC (p = 0.003). At preoper-
ativeworkup, the SCCgroup included a greater proportion of
cT4a cases than the adenocarcinoma group, and a lower
proportion of cT2 (p = 0.018). One hundred thirty-one
patients (84.5 % of the entire cohort) underwent surgery; the
McKeown procedure was used in 18 SCC patients. Six
patients (3.9 %) were not operated on because they had died
from treatment toxicity, and 18 (11.6 %) because they had
experienced disease progression, which was defined as
infiltration of unresectable structures or systemic neoplastic
diffusion after CRT, detected with CT, PET/CT, and/or
endoscopy. Radical resection (R0) was achieved in 123/155
patients (79.3 %); curative resection was more frequently
attained in adenocarcinoma (87.7 %) than in SCC (73.3 %)
(p = 0.043). When considering only patients undergoing
surgery, the R0 rate peaked at 93.8 % (123/131). Themedian
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number of retrieved nodes was 19 (3–80) (Table 2). One
patient (0.7 %) died in the postoperative period.
Pathological Response
Pathological complete response was achieved in 65
cases (41.9 %), and this percentage was not affected by
histotype (Table 2). If only the operated on patients were
taken into consideration, the percentage of pCR rose to
49.6 %.
Nodal metastases were found in 25 % of cases, with
2.2 ± 1.7 (mean ± standard deviation, SD) (median 1,
range 1–7) positive nodes per N? patient. The frequency of
nodal invasion and the number of positive nodes after CRT
tended to be higher in adenocarcinoma than in SCC, but the
difference did not achieve statistical significance (Table 2).
Survival
Five-year OS and DRS were respectively 43 % [95 %
confidence interval (CI) 34–52 %] and 49 % (39–58 %) in
the entire cohort of 155 patients. These figures rose to 50 %
(40–59 %) and 57 % (46–67 %), respectively, in the 131
operated on patients, and to 52 % (41–62 %) and 59 %
TABLE 1 Main demographic, clinical, and pathological characteristics of 155 patients undergoing neoadjuvant treatment
SCC (n = 90) Adenocarcinoma (n = 65) p value
Male/female ratio 66/24 (73/27) 60/5 (92/8) 0.003
Age (years) 60.9 ± 8.1 (60.8, 39.8–75.7) 61.5 ± 7.3 (61.3, 42.2–76.5) 0.667
cT stage 0.018
cT2 12 (13) 17 (26)
cT3 63 (70) 45 (69)
cT4a 15 (17) 3 (5)
cN stage 1.000
cN0 40 (44) 29 (45)
cN? 50 (56) 36 (55)
Patients undergoing surgery 73 (81) 58 (89) 0.185
R0 66 (73) 57 (88) 0.043
pCR 39 (43) 26 (40) 0.743
Qualitative variables expressed as number of cases (with percent frequency in parentheses); age expressed as mean ± SD (with median, range in
parentheses)
Significance of differences computed by Fisher’s exact test for qualitative variables and Wilcoxon–Mann–Whitney rank-sum test for age
TABLE 2 Main clinical and pathological characteristics of 131 patients undergoing surgery
SCC (n = 73) Adenocarcinoma (n = 58) p value
Size-based pathological response 0.469
pCR 39 (53) 26 (45)
MRD 12 (16) 7 (12)
NR 7 (10) 7 (12)
N? 15 (21) 18 (31)
Retrieved nodes 22.8 ± 15.6 (18, 3–80) 19.2 ± 7.4 (19, 3–42) 0.704
N? patients only
Positive nodes 1.7 ± 1.2 (1, 1–4) 2.7 ± 1.8 (2.5, 1–7) 0.057
N ratio (%) 13 ± 14 (6, 2–50) 19 ± 23 (11, 4–100) 0.164
Qualitative variables expressed as number of cases (with percent frequency in parentheses); quantitative variables expressed as mean ± SD (with
median, range in parentheses)
Significance of differences computed by Fisher’s exact test for qualitative variables and Wilcoxon–Mann–Whitney rank-sum test for quantitative
variables
pCR pathological complete response (ypT0 N0), MRD minimal residual disease (residual foci B 1 cm ypN0), NR nonresponse (residual foci
[1 cm ypN0). N? node-positive (ypN?)
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(48–69 %) when only R0 resections were considered.
Median OS and DRS were 36 and 50 months, respectively,
in the entire series. Median OS increased to 51 months in
patients operated on and further to 65 months in R0
patients, while median DRS was not reached by the end of
the follow-up in these selected groups.
Five-year OS and DRS were particularly high in pCR
cases, being respectively 72 % (57–82 %) and 81 %
(65–90 %).
Survival did not significantly differ between SCC and
adenocarcinoma in the entire cohort, in patients operated on,
and in the R0 group, while 5-year DRS was significantly
higher in pCR patients affected by adenocarcinoma (94 %,
63–99 %) than in those affected by SCC (70 %, 48–84 %)
(p = 0.025) (Fig. 1).
Recurrence
Seventy-eight patients died during follow-up: 66 from
cancer-related death and 12 from other causes, including
other primary malignancy. Among the patients undergoing
surgery, one died in the postoperative period and 41 from
relapse, while an additional 8 patients suffering from
recurrence were still alive at the end of follow-up. Half of
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FIG. 1 Disease-related
survival, estimated by Kaplan–
Meier method, in a series of
patients with locally advanced
esophageal cancers, as a
function of histotype (squamous
cell carcinoma vs
adenocarcinoma). Significance
of differences between survival
curves evaluated by log-rank
test
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relapses (25/49 = 51 %) were systemic (mostly liver, lung,
and brain), while mixed relapses, meaning both systemic
and locoregional, and solo locoregional were equally
common, affecting 12 patients (24.5 %) each.
The pattern of recurrence was mainly systemic (19/24)
in adenocarcinoma, while locoregional and mixed relapses
were more common in SCC (Table 3).
Cancer recurrence was found even in 11 pCR patients
(16.9 %), of whom 6 presented systemic relapse. Among
relapsing pCR patients, two of the three cases with loco-
regional recurrence had received suboptimal
lymphadenectomy with only four and six harvested nodes,
respectively, so that stage migration cannot be excluded.
Of note, pCR patients who had suffered from adenocarci-
noma less frequently developed relapse (3/26), which was
always systemic.
DISCUSSION
According to recent systematic reviews, meta-analyses,
and the recent CROSS trial, adoption of neoadjuvant che-
motherapy or chemoradiotherapy has led to a 20–35 %
decrease in mortality risk as compared with surgery alone
in locally advanced esophageal cancer.3–7,11,12 The
advantages of preoperative treatment consist in the down-
staging and downsizing of the primary tumor along with
clearance of possible circulating neoplastic cells. This
translates into an increased rate of radical resection (R0)
and a nonnegligible rate of pathological complete response
(pCR), achieved in up to 40 % of cases in several
studies.3–6,8,13
Chemoradiotherapy has been advocated to increase local
control, with better survival and higher rate of both R0
resection and pCR than chemotherapy alone.5,14,15 Hence,
CRT is now considered the standard of care by many
centers for the treatment of locally advanced esophageal
cancer.
In the present study a protocol of concurrent CRT, based
on 5-FU, cisplatin, and docetaxel along with 50.4 Gy of
concurrent radiotherapy, was found to provide good long-
term survival, with 59 % 5-year DRS for R0 patients after
median follow-up of 46 months. Also, the R0 rate was
notable, amounting to 93.8 % of the operated on cases.
Nonetheless this protocol presented significant toxicity,
leading to death in 3.9 % of treated patients, so that its use
should be restricted to specialized centers. Surgery instead
was not affected by CRT, postoperative mortality being
reasonably low (0.7 %). Noteworthily, this study was car-
ried out in a single high-volume center, with [40
esophagectomies performed per year, and mortality is
consistent with that reported by other high-volume
centers.16–18
The present results were compared with those of recent
phase II trials with different protocols, but always includ-
ing cisplatin.19–23 The present study achieved the highest
proportion of patients operated on (85 %) with respect to
the other trials (range 69–83 %), while the proportion of
pCR (42 %) fell within the range (16–49 %). Overall sur-
vival in the present study was either similar to or higher
than that reported by the other trials.19,21–23
Adenocarcinoma Versus SCC
Adenocarcinoma and SCC, although being different
nosological entities, have similar survival after induction
chemoradiation.3,5 This survival similitude was confirmed
by the present investigation, except for pCR patients, who
presented better OS and DRS when affected by adenocar-
cinoma than by SCC. Survival was not statistically
different between the two histotypes also in a German and
a US trial.24,25 However, both studies found a higher rate of
pCR in SCC, while in our experience the pCR rate was
similar between the two groups. Furthermore, the US study
reported excellent local control in SCC, with only systemic
relapses, while adenocarcinoma was burdened with loco-
regional failure. The opposite was found in the present
study, where adenocarcinoma had mainly systemic recur-
rence, while in SCC also locoregional failure was found.
Relapse
The locoregional relapse rate is reported to be lower
after neoadjuvant CRT, accounting for about one-third of
the total recurrence rate.4,26,27 The solo locoregional
recurrence rate was only 24.5 % in our experience and
even lower (21 %) in a US study.25
Other recent studies found a lower recurrence rate after
CRT than after surgery alone, particularly in responders to
treatment.27,28 Nevertheless, a nonignorable recurrence rate
was found also in pCR patients both in the current literature
(18–24 %) and in our experience (16.9 %), and these
recurrences were mainly systemic, as in the present
investigation.27–29
TABLE 3 Pattern of cancer relapse in 131 patients undergoing
surgery
SCC (n = 73) Adenocarcinoma (n = 58) p value
Type of relapse 0.001
Locoregional 9 (12.3) 3 (5.2)
Mixed 10 (13.7) 2 (3.5)
Systemic 6 (8.2) 19 (32.8)
Relapses expressed as number of cases (with percent frequency in
parentheses). Significance of differences computed by Fisher’s exact
test
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pCR
Responders to therapy, in particular pathological com-
plete responders, have better prognosis than nonresponders,
so that in the current literature pCR is deemed a surrogate
of treatment efficacy, with prolonged survival.3–6,8,30–32
We found a very high percentage of pCR in our series,
which reached 50 % in operated on patients. A remarkable
pCR rate was also reported by the abovementioned phase II
trials, ranging between 16 and 49 % with a median of
40 %. In the present study, 5-year OS and DRS in pCR
patients were respectively 72 % and 81 %, which is even
higher than the 50 % pooled survival computed by a recent
review and in line with the best results reported.30–32
In the era of tailored treatment development, when two
randomized trials on SCC reported that definitive CRT allows
achievement of survival comparable to neoadjuvant CRT
followed by surgery, it could be hypothesized that a high
percentage of patients are overtreated, as they routinely
undergo a surgical procedurewhich could be rather performed
only on demand, in case of relapse during follow-up.33–35
On the other hand, nonresponders to treatment suffer from
the risks related to chemoradiation, without any survival
benefit. This is also supported by a very recent trial, where
patients treated with upfront surgery presented a survival
benefit with respect to nonresponders to neoadjuvant CRT,
later operated on.36 However, it is almost impossible to
identify or foresee the responders to treatment, even if
molecular biology markers of response are being investi-
gated.37–40 Until pretreatment markers of response become
available, standardized protocols of CRT are needed for all
fit patients. We believe that the chance of obtaining down-
staging up to complete response is so high that it is better to
risk treatment toxicity than to perform upfront surgery.
Hence, the first steps towards tailored treatment could be
identifying nonresponders to CRT at an early stage and
avoiding surgery for complete responders.
The only study that documented a change in therapeutic
strategy during treatment was the MUNICON trial, where
PET/CT was employed to distinguish, early during treat-
ment, the patients who probably would not benefit from
further chemotherapy.41 However, the abovementioned
study focused on chemotherapy alone in patients with
adenocarcinoma, and its findings could not be replicated
for CRT and for SCC. Piessen et al. demonstrated a sur-
vival benefit only when R0 resection was obtained and
proposed aortic contact and tumor height at barium swal-
low as markers of resectability.42 Of course, the decision to
give up surgery must be taken case by case.
So far the possibility to interrupt induction treatment in
selected patients is merely hypothetical, and surgical
treatment remains mandatory for all the patients without
progression during treatment.
Surgery in clinical complete responders might be con-
sidered overtreatment; nonetheless, two main problems
exist: first, it is to date impossible to reliably define a
clinical complete response and, second, the risk of pCR
failure is not negligible, being around 20 % in the current
literature and 16.9 % in the present study.
Noteworthily, only three relapses were observed in the
26 pCR cases with adenocarcinoma, which in addition
were systemic relapses. These observations suggest that
surgery on demand could be first experimentally applied to
clinical complete responders in the adenocarcinoma group.
However, as long as no staging techniques able to define a
clinical complete response exist, surgery on demand
remains just hypothetical even in these patients.
In conclusion, a neoadjuvant CRT based on cisplatin,
5-FU, and docetaxel, along with concurrent radiotherapy,
can achieve good results in terms both of survival and of
radical resection and pCR rate. In our opinion, the benefits
of this protocol largely compensate the nonnegligible tox-
icity. At present, surgery on demand cannot be devised
even for patients with lower risk of relapse, as rigorous
assessment of clinical response is still lacking.
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